Additional file 2 of N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis

Additional file 2: Table S4. The merged gene expression matrix from E-MTAB-69 and E-MTAB-2374 via batch-normalization. Table S5. The 13 m6A RNA methylation regulators in the merged data set. Table S6. The differentially expressed analysis of the 13 m6A RNA methylation regulators between MS patients and non-MS controls. Table S7. Identification of differentially expressed genes (DEGs) between MS patients and non-MS controls. Table S8. The gene ontology (GO) analysis of the DEGs. Table S9. The gene ontology (GO) analysis of the 13 m6A RNA methylation regulators. Table S10. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of the DEGs. Table S11. The clinical characteristic in the training set (n = 41).

补充材料2：附表S4：经批次标准化处理后，整合自E-MTAB-69与E-MTAB-2374的基因表达矩阵。
附表S5：整合数据集中的13个m6A RNA甲基化调控因子（m6A RNA methylation regulators）。
附表S6：多发性硬化（Multiple Sclerosis, MS）患者与非MS对照人群中13个m6A RNA甲基化调控因子的差异表达分析结果。
附表S7：多发性硬化患者与非MS对照人群间差异表达基因（differentially expressed genes, DEGs）的鉴定结果。
附表S8：差异表达基因的基因本体（Gene Ontology, GO）富集分析结果。
附表S9：13个m6A RNA甲基化调控因子的基因本体（GO）富集分析结果。
附表S10：差异表达基因的京都基因与基因组百科全书（Kyoto Encyclopedia of Genes and Genomes, KEGG）通路分析结果。
附表S11：训练集的临床特征信息（n=41）。